Application of ursolic acid in preparation of medicine for treating corneal epithelium injury
By using eye drops dissolved in buffer solution, the treatment problem of corneal epithelial injury, especially dry eye disease, achieved non-toxic side effects and reduced inflammation, significantly improved corneal epithelial barrier function and tear fluid. secretion.
Patent Information
- Application Number
- CN202411222624.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-02
- Publication Date
- 2024-11-29
AI Technical Summary
The prior art is difficult to effectively treat corneal epithelial injury, especially corneal epithelial injury caused by dry eye disease, and common eye drops have problems with local and systemic toxic side effects.
Urtrolic acid is used as the main ingredient to prepare eye drops, gels or pastes by dissolving them in buffer solutions or solubilizing agents, which are used to promote corneal epithelial repair, reduce inflammation, maintain the number of conjunctival goblet cells and tear secretion. Treatment plans that form non-toxic side effects.
Urgo acid significantly promotes tear secretion, repairs corneal damage, enhances corneal epithelial barrier function, reduces inflammatory infiltration, maintains conjunctiva health, and has no toxic side effects in the range of 1 to 30μg/mL. It is suitable for corneal epithelium caused by various eye diseases. damage.
Smart Images

Figure CN119033793A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of pharmaceutical chemistry, and in particular to application of ursolic acid in preparing a drug for treating corneal epithelial damage. Background Art
[0002] The cornea is a transparent structure in the anterior segment of the eye, which plays an important role in protecting the eyeball and maintaining refraction. Corneal epithelial injury refers to a pathological state in which the barrier function and structural integrity of the corneal epithelium are destroyed due to various factors, causing partial or full loss of the corneal epithelium. It includes ocular surface diseases such as dry eyes, meibomian gland dysfunction, ocular trauma, infectious or non-infectious keratitis, corneal chemical injury, Sjogren syndrome, Stevens-Johnson syndrome, Mooren corneal ulcer, blepharitis, blepharitis, trichiasis, etc., mainly manifested as diffuse punctate loss or erosion of the corneal epithelium. Corneal epithelial injury can cause pain and visual impairment, seriously affecting the patient's visual quality. Early diagnosis and early treatment of corneal epithelial injury are extremely important, which can significantly improve the patient's visual prognosis, reduce complications, improve the quality of life, and reduce the economic burden. Therefore, it is of great value to develop an eye drop drug with good efficacy, long-term use and no obvious local and systemic toxic and side effects for the treatment of corneal epithelial injury. Summary of the invention
[0003] In view of the defects in the prior art, the present invention proposes the use of ursolic acid in the preparation of a drug for treating corneal epithelial damage.
[0004] The present invention provides an application of ursolic acid in preparing a medicine for treating corneal epithelial damage caused by a disease.
[0005] Ursolic acid (also known as ursolic acid) is a pentacyclic triterpenoid compound isolated from bearberry, and is the main active ingredient of bearberry for clearing liver and purging fire, improving eyesight, and has multiple biological effects such as anti-inflammatory, antibacterial, antioxidant, and anti-diabetic. The present invention has found through research that ursolic acid has repair activity on damaged corneal epithelium, can promote ocular surface tissue repair, increase corneal epithelial barrier function, inhibit ocular surface inflammation, maintain the number of conjunctival goblet cells, reduce lacrimal gland and meibomian gland atrophy, promote tear secretion, and maintain tear film stability.
[0006] In some embodiments, ursolic acid is the only active ingredient in the drug.
[0007] In some embodiments, the disease is any one of dry eye, meibomian gland dysfunction, ocular trauma, infectious keratitis, non-infectious keratitis, chemical corneal injury, Sjogren's syndrome, Stevens-Johnson syndrome, Mooren corneal ulcer, blepharitis, blepharitis, or trichiasis.
[0008] In some embodiments, the dosage form of the drug is any one of eye drops, gels, ointments, and emulsions, preferably eye drops.
[0009] In some embodiments, the drug is loaded in the following manner:
[0010] Dissolve ursolic acid in a buffer solution or a pharmaceutically acceptable solubilizing agent.
[0011] In some embodiments, the solubilizing agent is at least one of sodium bicarbonate solution, lecithin, lactic acid, glycerol, polyvinyl alcohol, soybean lecithin or poloxamer.
[0012] In some embodiments, the concentration of ursolic acid is 1 to 30 μg / mL.
[0013] In summary, compared with the prior art, the present invention achieves the following technical effects:
[0014] 1. The ursolic acid of the present invention can significantly promote the tear secretion of dry eye mice and effectively relieve dry eye symptoms. Ursolic acid can not only significantly repair corneal damage, enhance the barrier function of corneal epithelium, effectively protect the cornea, but also improve the morphology of corneal epithelium and reduce inflammatory infiltration. In addition, ursolic acid helps to maintain the number of conjunctival goblet cells, promotes the secretion of mucin, and further improves the barrier function of corneal epithelium. It reduces the infiltration of inflammatory factors in the conjunctiva, promotes the repair of corneal epithelium, and improves the health of the conjunctiva.
[0015] 2. The ursolic acid of the present invention is within the range of 1 to 30 μg / mL, and has no toxic side effects when continuously used in the eye. It can be used to repair corneal epithelial damage caused by various eye diseases, especially corneal epithelial damage caused by dry eye. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.
[0017] Figure 1 The test result of the tear secretion amount after the liquid medicine treatment of the present invention;
[0018] Figure 2 This is a corneal fluorescein sodium staining image after being treated with the drug solution of the present invention;
[0019] Figure 3 This is a laser confocal image of the cornea after being treated with the drug solution of the present invention;
[0020] Figure 4 This is an optical tomography image of the anterior segment of the eye after being treated with the drug solution of the present invention;
[0021] Figure 5 This is a HE staining image of the cornea and conjunctiva after being treated with the drug solution of the present invention;
[0022] Figure 6 This is a PAS staining image of conjunctival goblet cells after being treated with the drug solution of the present invention;
[0023] Figure 7 The detection result of conjunctival inflammatory factors after treatment with the liquid medicine of the present invention;
[0024] Figure 8 This is an immunofluorescence staining image of the cornea and conjunctiva after being treated with the drug solution of the present invention. DETAILED DESCRIPTION
[0025] In order to enable those skilled in the art to better understand the scheme of the present invention, the technical scheme in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are only embodiments of a part of the present invention, not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work should fall within the scope of protection of the present invention.
[0026] The experimental methods used in the following examples are conventional methods unless otherwise specified. The materials and reagents used are all commercially available unless otherwise specified.
[0027] Ursolic acid: U820363, Maclean, Shanghai, China.
[0028] Example 1
[0029] Accurately weigh 1.00 mg of ursolic acid, add 20 mL of phosphate buffer to dissolve, vortex evenly, and ultrasonicate at 50°C for 1 h to obtain a 50 μg / mL stock solution. Take 24 μL of the stock solution and add 976 μL of phosphate buffer to obtain 1 mL of 1.2 μg / mL drug solution.
[0030] Example 2
[0031] Accurately weigh 1.00 mg of ursolic acid, add 20 mL of phosphate buffer to dissolve, vortex evenly, and ultrasonicate at 50°C for 1 h to obtain a 50 μg / mL stock solution. Take 120 μL of the stock solution and add 880 μL of phosphate buffer to obtain 1 mL of 6 μg / mL drug solution.
[0032] Example 3
[0033] Accurately weigh 1.00 mg of ursolic acid, add 20 mL of phosphate buffer to dissolve, vortex evenly, and ultrasonicate at 50°C for 1 h to obtain a 50 μg / mL stock solution. Take 600 μL of the stock solution and add 400 μL of phosphate buffer to obtain 1 mL of 30 μg / mL drug solution.
[0034] Example 4
[0035] Accurately weigh 1.00 mg of ursolic acid, add 20 mL of phosphate buffer to dissolve, vortex evenly, and ultrasonicate at 50°C for 12 h to obtain a 50 μg / mL stock solution. Take 120 μL of the stock solution and add 880 μL of phosphate buffer to obtain 1 mL of 6 μg / mL drug solution.
[0036] The therapeutic effect of the 6 μg / mL ursolic acid eye drops prepared in Example 4 on the corneal epithelial injury mouse model was evaluated, and the specific steps were as follows:
[0037] 1. Establishment of a mouse model of dry eye-related corneal epithelial injury
[0038] Female C57BL / 6 mice aged 8 to 12 weeks were subcutaneously injected with scopolamine injection (prepared with phosphate buffer, concentration of 0.25g / 100mL), 0.2mL each time, 4 times a day, for 7 consecutive days; at the same time, the mice were instilled with benzalkonium chloride solution (prepared with DDW (double distilled water) with a concentration of 0.75g / 100mL), 2μL each time, once a day, for 7 consecutive days. The mice were raised in a dry and ventilated environment (RH = 30±3%, T = 23-25℃), with a 12h light-dark cycle, and fed with standard food.
[0039] 2. Experimental methods
[0040] A control group (CTRL), a model group (MODEL), a solvent group (VEHICLE) and a treatment group (MC-UA) were set up. The control mice in the control group were not subjected to model treatment or treatment and were kept in a normal environment. The model mice in the model group were not treated. The mice in the solvent group were treated with phosphate buffered saline (PBS) for corneal injury model mice, one drop (about 2 μL) each time, 4 times a day, in both eyes, and continued to use the drug for 7 days. The treatment group was treated with ursolic acid eye drops for corneal epithelial injury model mice, one drop (about 2 μL) each time, 4 times a day, in both eyes, and continued to use the drug for 7 days.
[0041] 3. Phenol red cotton thread test to detect tear secretion
[0042] On the 8th day after medication, phenol red cotton thread was used to detect the tear secretion of mice. Under the slit lamp, ophthalmic forceps were used to place the phenol red cotton thread at the conjunctival fornix below the outer canthus of the mouse eye. After 15 seconds, the length of the phenol red cotton thread was measured with a millimeter ruler. The measurement was repeated 3 times to obtain the average value and record the results. Figure 1shown.
[0043] The results showed that the tear secretion of the ursolic acid eye drops treatment group increased significantly. Statistical analysis of the tear secretion of the three groups showed that the difference between the model group and the medication group was statistically significant. The results indicate that topical eye drops can promote tear secretion.
[0044] 4. Corneal fluorescein sodium staining
[0045] On the 8th day after medication, the corneal epithelial damage of mice was detected by slit lamp fluorescence staining. After anesthetizing the mice with sodium pentobarbital, the whiskers of the mice were cut with external eye scissors, the cornea was cleaned with saline, the eyeball was fully exposed, the mouse cornea was kept perpendicular to the light source, and the image was captured under the white light of the slit lamp. 2 μL of sodium fluorescein solution was drawn with a pipette and dropped into the lower conjunctival sac of the mouse, the eyes were manually blinked several times, the conjunctival sac was rinsed with saline several times, the excess dye and saline solution in the conjunctival sac were absorbed with filter paper, the eyeball was fully exposed, and the corneal epithelial fluorescence staining was photographed under the blue light of the slit lamp. The results are as follows: Figure 2 shown.
[0046] The results showed that the number of corneal punctate staining in the ursolic acid eye drops treatment group was significantly less than that in the model group, and no flake staining was observed. The results indicate that topical eye drops can significantly reduce corneal epithelial damage and have the function of protecting the corneal epithelial barrier.
[0047] 5. Corneal laser confocal
[0048] On the 8th day after medication, corneal epithelial damage in mice was detected using corneal laser confocal microscopy. After anesthetizing the mice with sodium pentobarbital, the whiskers of the mice were cut off with external eye scissors. The cornea was cleaned with saline, carbomer gel was applied to the cornea, the eyeball was fully exposed, and the mouse cornea was kept perpendicular to the light source. The corneal laser confocal microscopy was adjusted to different focal lengths to capture images of the tissue structure at different levels of the cornea. The results are shown in the figure. Figure 3 shown.
[0049] The results showed that compared with the model group, the ursolic acid eye drops treatment group had less epithelial cell detachment in the corneal epithelium and significantly less inflammatory infiltration in the stromal layer. The results showed that topical eye drops treatment with ursolic acid eye drops can significantly improve corneal structure, reduce corneal inflammatory infiltration, and protect epithelial structure.
[0050] 6. Anterior segment optical coherence tomography (OCT)
[0051] On the 8th day after medication, the corneal epithelial damage of the mice was detected by anterior segment laser confocal microscopy. After the mice were anesthetized with sodium pentobarbital, the whiskers of the mice were cut with external eye scissors. The cornea was cleaned with saline, the pupil was dilated with tropicamide, the eyeball was fully exposed, the mouse cornea was kept perpendicular to the light source, and the pupil was facing the light source, and the corneal image was taken with an optical correlation tomography scanner. The results are shown in Figure 4 shown.
[0052] The results showed that compared with the model group, the corneal epithelial loss in the ursolic acid eye drops group was significantly improved and the inflammatory cell infiltration was reduced. The results showed that topical eye drops can significantly repair corneal damage and reduce inflammatory infiltration.
[0053] 7. HE staining of conjunctival goblet cells
[0054] The mice were killed by cervical dislocation, and the whole eyeballs (including conjunctival sacs) of the mice were removed and made into paraffin specimens, which were cut into 5 μm slices and stained with hematoxylin-eosin (HE). The specific steps are as follows:
[0055] 1) Dewaxing of paraffin sections: immersion in xylene (xylene 1): 15 min, then immersion in xylene (xylene 2): 15 min, 100% ethanol: 5 min, 95% ethanol: 5 min, 90% ethanol: 5 min, 80% ethanol: 5 min;
[0056] 2) Soak the tissue specimen in deionized water for 10 minutes;
[0057] 3) Gently shake dry and stain the tissue specimen with hematoxylin for 5 minutes;
[0058] 4) Take out the tissue specimen, rinse it slowly with tap water to remove the hematoxylin, and wash the tissue specimen with running water for 5 minutes;
[0059] 5) 1% hydrochloric acid alcohol differentiation for 10 seconds;
[0060] 6) Rinse with running water for 5 minutes;
[0061] 7) Stain the tissue specimen in eosin tank for 5 minutes;
[0062] 8) Rinse with tap water to remove floating color;
[0063] 9) Dehydration: 80% ethanol: 2 min, 95% ethanol: 2 min, 100% ethanol: 2 min, xylene 1: 2 min, xylene 2: 2 min;
[0064] 10) Seal the slide.
[0065] The stained tissue specimens were placed under an electron microscope to observe the morphology of the cornea and conjunctiva. Figure 5As shown. The results showed that the smoothness of the corneal epithelium increased, the desquamated epithelium decreased, and the inflammatory infiltration decreased in the ursolic acid eye drops treatment group; the number of conjunctival goblet cells increased compared with the model group. Statistical analysis of the number of conjunctival goblet cells in the four groups showed that the difference between the model group and the medication group was statistically significant. The above results indicate that topical eye drops can significantly improve the morphology of the corneal epithelium, promote corneal epithelial repair, and increase the number of goblet cells.
[0066] 8. PAS staining of conjunctival goblet cells
[0067] The mice were killed by cervical dislocation, and the whole eyeballs (including conjunctival sacs) of the mice were removed and made into paraffin specimens, which were cut into 5 μm slices and stained using a periodic acid-Schiff kit. The specific steps are as follows:
[0068] 1) Dewaxing of paraffin sections: xylene 1: 15 min, xylene 2: 15 min, 100% ethanol: 5 min, 95% ethanol: 5 min, 90% ethanol: 5 min, 80% ethanol: 5 min.
[0069] 2) Soak the tissue specimen in deionized water for 10 minutes;
[0070] 3) Gently shake dry and cover the tissue specimen on the slide with periodic acid for 10 minutes;
[0071] 4) Soak the tissue specimen in deionized water for 10 minutes;
[0072] 5) Wipe off the deionized water and cover the tissue specimen on the slide with Schiff's reagent for 8 minutes;
[0073] 6) Reddening: Gently shake the slide, then cover the tissue specimen on the slide with deionized water for 2-3 minutes, pour out the deionized water and observe under the microscope;
[0074] 7) Cover the tissue specimen on the slide with tap water for 1 min;
[0075] 8) Cover the tissue specimen on the slide with hematoxylin for 35 seconds;
[0076] 9) Rinse repeatedly with tap water;
[0077] 10) Differentiate with hydrochloric acid alcohol for 1 second;
[0078] 11) Rinse with tap water for 5 minutes;
[0079] 12) Dehydration: 80% ethanol: 2 min, 95% ethanol: 2 min, 100% ethanol: 2 min, xylene 1: 2 min, xylene 2: 2 min;
[0080] 13) Seal the slide.
[0081] The stained tissue specimens were placed under an electron microscope to observe the morphology and number of conjunctival goblet cells. Figure 6 As shown. The results showed that the number of conjunctival goblet cells in the ursolic acid eye drops treatment group increased significantly. Statistical analysis of the number of conjunctival goblet cells in the four groups showed that the difference between the model group and the medication group was statistically significant. The above results indicate that topical eye drops can maintain the number of goblet cells, increase mucin secretion, and promote the repair of corneal epithelium.
[0082] 9. Real-time fluorescence quantitative PCR detection of conjunctival inflammatory factor expression
[0083] Extraction of RNA from mouse conjunctival tissue:
[0084] (1) The mice were killed by cervical dislocation. Fresh conjunctival tissue was removed on ice and placed in a 1.5 mL centrifuge tube containing pre-cooled Tirzol. The conjunctival tissue was cut into pieces and homogenized. The tube was quickly placed in liquid nitrogen. 500 μL of pre-cooled chloroform was added. The tube was placed on an oscillator and vigorously shaken to mix. The tube was placed in a 4°C centrifuge at 12,000 rpm for 5 min. The supernatant was transferred to a new 1.5 mL centrifuge tube. 700 μL of isopropanol was added and mixed thoroughly. The tube was placed in a -80°C refrigerator and frozen for 15 min. The tube was then placed in a 4°C centrifuge at 12,000 rpm for 5 min. The supernatant was discarded.
[0085] (2) Add 1 mL of 70% ethanol prepared with DEPC water to the product obtained in step (1), mix by inversion, place in a centrifuge at 4°C, 12,000 rpm, centrifuge for 5 min, discard the supernatant, and repeat twice.
[0086] (3) The product obtained in step (2) was placed in a centrifuge at 4°C, 12,000 rpm, and centrifuged for 3 min. The residual liquid was carefully aspirated and placed in a fume hood to dry for 15 min.
[0087] (4) Add an appropriate amount of DEPC water to the product obtained in step (3) to dissolve RNA, and simultaneously add an appropriate amount of RNase inhibitor to obtain an RNA solution. After measuring the RNA concentration, store the solution at -80°C.
[0088] Primer dilution:
[0089] (1) Place the EP tube containing the primers into a low-temperature centrifuge, adjust the speed to 12,000 rpm, and centrifuge for 5 minutes.
[0090] (2) Gently open the EP tube cap and slowly add DEPC water along the tube wall to fully shake and dissolve the primer powder to obtain the primer storage solution.
[0091] (3) Use a pipette to draw 10 μL of primer storage solution, add 90 μL of DEPC water to prepare primer working solution, shake thoroughly to mix, and store at -20°C.
[0092] The primer sequences used are shown in Table 1:
[0093] Table 1 Real-time fluorescence PCR primer sequences
[0094]
[0095] RNA Reverse Transcription:
[0096] Refer to the system in Table 2 for reverse transcription, mix well and centrifuge briefly, then perform reverse transcription on a machine.
[0097] Table 2 Reverse transcription reaction system
[0098]
[0099] Reaction conditions: 37℃ 15min, 85℃ 5sec, terminate at 4℃. After the reverse transcription reaction, store the cDNA at -20℃.
[0100] Real-time PCR assay:
[0101] The real-time PCR system is shown in Table 3:
[0102] Table 3 Real-time PCR system
[0103] Reagents volume Forward Primer 0.2μL Reverse Primer 0.2μL cDNA 1μL SYBR Premix Ex Taq 5μL DEPC water 3.6μL
[0104] Real-time PCR reaction steps: 95°C 10s, 95°C 5s, 60°C 35s. 40 cycles were preset, and melting curve analysis was performed on the product after the real-time PCR amplification was completed.
[0105] Calculation of relative gene expression fold:
[0106] Data processing and analysis were performed using ABI StepOne Software v1.4 to obtain the amplification curves and CT values of each reaction. The CT value represents the number of cycles when the fluorescence signal in each reaction tube reaches the set threshold. Three replicate wells were made for each sample, and the average CT value was taken into the calculation using the formula: POWER(2,(CT 样本 -CT 样本actin )-(CT Control -CT Control actin ) to obtain the relative gene expression multiple.
[0107] The results are as follows Figure 7The results showed that the expression of conjunctival inflammatory factors NOS2, IL-6, IFN-γ and IL17 in the ursolic acid eye drops treatment group was significantly reduced, and the expression of anti-inflammatory factor IL13 was significantly increased. The difference between the treatment group and the model group was statistically significant. This shows that local eye drops have good anti-inflammatory and immunosuppressive effects.
[0108] 10. Immunofluorescence staining: The mice were killed by cervical dislocation, and the whole eyeballs (including conjunctival sacs) of the mice were removed and made into paraffin specimens, which were cut into 5 μm slices for MMP3, MUC5A, and CD4 + , TNF-α and other antibodies immunofluorescence staining. The specific steps are as follows:
[0109] 1) Dewaxing of paraffin sections: xylene 1: 15 min, xylene 2: 15 min, 100% ethanol: 5 min, 95% ethanol: 5 min, 90% ethanol: 5 min, 80% ethanol: 5 min;
[0110] 2) Soak the tissue specimen in tap water for 10 minutes;
[0111] 3) Cover the specimen with 3% hydrogen peroxide for 10 minutes to remove catalase;
[0112] 4) Cover the tissue specimen with phosphate buffered saline (PBS) for 10 min;
[0113] 5) Infiltrate the specimen with antigen retrieval solution and boil it in a microwave oven for 10 minutes;
[0114] 6) Cover the tissue specimen with phosphate buffered saline (PBS) for 10 min;
[0115] 7) Cover the specimen with 0.2% permeabilization solution (Triton) for 10 min, and cover the tissue specimen with PBS for 10 min;
[0116] 8) Wipe off PBS, block tissue specimens with 2% BSA for 1 hour, cover tissue specimens with phosphate buffered saline (PBS) for 10 minutes, and repeat the PBS covering process three times;
[0117] 9)MMP3(1:200), MUC5A(1:200), CD4 + (1:200), TNF-α (1:200) were used to cover the tissue specimens and stored in a 4°C refrigerator overnight;
[0118] 10) Cover the tissue specimen with PBS for 10 min each time, repeated three times;
[0119] 11) Cover the tissue specimen with secondary antibody (1:300) and incubate at room temperature for 1 hour in the dark;
[0120] 12) Cover the tissue specimen with PBS for 10 min each time, repeated three times;
[0121] 13) Wipe off the PBS and mount the slides with mounting medium containing DAPI.
[0122] The stained tissue specimens were observed under a confocal microscope and the expression of MMP3, MUC5A, and CD4 + , the fluorescence expression of TNF-α on the cornea or conjunctiva, the results are as follows Figure 8 The results showed that the corneal MMP3 in the ursolic acid eye drops treatment group was significantly reduced, the conjunctival MUC5A was significantly increased, and the CD4 + , TNF-α were significantly reduced. + Statistical analysis of the expression of TNF-α fluorescence showed that the difference between the model group and the medication group was statistically significant. The above results indicate that topical eye drops of ursolic acid can improve the corneal epithelial barrier function, increase the expression of mucin on the ocular surface, reduce the infiltration of conjunctival inflammatory cells and the secretion of inflammatory factors, and promote the repair of corneal epithelium.
[0123] The present invention can also generate multiple embodiments according to the type of ingredients, ingredient content, dosage form, etc. For example:
[0124] Embodiment 1: A gel with ursolic acid as an effective ingredient;
[0125] The effective amount of ursolic acid and an appropriate amount of aqueous gel matrix are included. According to the gel of the present invention, the effective amount of ursolic acid refers to the content of ursolic acid required for the effect according to the usual usage.
[0126] Ophthalmic gels have a high viscosity and can form a thin film on the surface of the eye, prolonging the retention time of the drug in the conjunctival sac, thereby increasing drug absorption.
[0127] Embodiment 2: Ointment with ursolic acid as an effective ingredient;
[0128] The invention comprises an effective amount of ursolic acid and an appropriate amount of any one or more of base oil, thickener, lubricant, stabilizer and pH regulator.
[0129] The viscous texture of the ointment can form a long-lasting protective film on the surface of the eye, thereby prolonging the residence time of the drug and increasing the durability of the drug effect. It can gradually release the drug and provide a continuous therapeutic effect. This is especially important for eye diseases that require long-term symptom control.
[0130] Embodiment 3: an emulsion with ursolic acid as an active ingredient;
[0131] The invention comprises an effective amount of ursolic acid and an appropriate amount of any one or more of an emulsifier, a lubricant, a stabilizer, a pH regulator and a buffer.
[0132] Emulsions can help improve the stability of drugs in the eye, especially for some unstable or easily decomposed drugs. The oil component in the emulsion can help the drug better penetrate the cornea of the eye and enhance the bioavailability of the drug.
[0133] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
[0134]
Claims
1. Application of ursolic acid in the preparation of drugs for treating corneal epithelial damage caused by diseases.
2. The use according to claim 1, It is characterized in that In the medicine, ursolic acid is the only effective ingredient.
3. The use according to claim 1, It is characterized in that The disease is any one of dry eye, meibomian gland dysfunction, ocular trauma, infectious keratitis, non-infectious keratitis, corneal chemical injury, Sjogren's syndrome, Stevens-Johnson syndrome, Mooren corneal ulcer, blepharitis, blepharitis or trichiasis.
4. The use according to claim 1, It is characterized in that The dosage form of the drug is any one of eye drops, gel, ointment and emulsion.
5. The use according to claim 1, It is characterized in that The drug delivery method of the drug is: Dissolve ursolic acid in a buffer solution or a pharmaceutically acceptable solubilizing agent.
6. The use according to claim 5, It is characterized in that The dissolution-promoting solubilizing agent is at least one of sodium bicarbonate solution, lecithin, lactic acid, glycerol, polyvinyl alcohol, soybean lecithin or poloxamer.
7. The use according to claim 5, It is characterized in that The concentration of the ursolic acid is 1-30 μg / mL.
